Suppressing Agents for Anticancer Therapy Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Anticancer therapies, particularly those involving immune checkpoint inhibitors, often cause adverse events such as toxicities, which can lead to discontinuation of treatment and compromise patient outcomes.
Innovation Solution
Administering a suppressing agent in conjunction with or following anticancer therapy to mitigate adverse events, using combinations of anticancer agents like immune checkpoint inhibitors, cytokines, and live bacterial products that induce specific immune responses to enhance treatment efficacy while reducing toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immune checkpoint inhibitors are administered to improve cancer treatment efficacy, then survival rates improve, but adverse events and toxicities increase
Solution Approach 1:
The patent introduces a suppressing agent as an intermediary substance that mediates between the immune checkpoint inhibitor and the patient's body. This suppressing agent specifically targets and reduces adverse events and toxicities while allowing the immune checkpoint inhibitor to maintain its anti-cancer efficacy, thus resolving the contradiction between treatment effectiveness and side effect management
Solution Approach 2:
The patent converts the harmful adverse events and toxicities caused by immune checkpoint inhibitors into a manageable condition by using suppressing agents. The harmful immune activation is transformed into a controlled response where the beneficial anti-cancer immunity is preserved while the harmful side effects are suppressed and converted into treatable symptoms
2Reliability
If traditional chemotherapy is used to treat cancer, then cancer cells are killed, but severe adverse events such as nausea and hair loss occur
Solution Approach 1:
The patent uses a suppressing agent as a mediator that specifically protects normal cells from the harmful effects of chemotherapy while allowing the chemotherapy to continue killing cancer cells. This intermediary substance reduces the direct toxic impact on healthy tissues, thereby decreasing adverse events like nausea and hair loss without compromising the anti-cancer mechanism
Data Source
AI summary
Provided herein are compositions, methods, and kits for the treatment of cancer. The disclosure also provides compositions, methods, and kits that suppress adverse events caused by anticancer therapy.